Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: A dose-finding study

M. Reni, S. Cereda, E. Bonetto, M. G. Viganô, P. Passoni, A. Zerbi, G. Balzano, R. Nicoletti, C. Staudacher, V. Di Carlo

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study was to assess the maximum tolerated dose (MTD) of an intensified PEFG regimen administered every 14 days to patients with Stage III or metastatic pancreatic adenocarcinoma. Twenty-nine patients received fixed doses of both epirubicin (30 mg/m2) and 5-fluorouracil (200 mg/m2/day on Days 1-14) and of escalating doses of cisplatin and gemcitabine. The MTD was cisplatin 30 mg/m2 and gemcitabine 800 mg/m2. With respect to classical PEFG, intensified regimen potentially improved the dose-intensity of both cisplatin and epirubicin by 50 percent and of gemcitabine by 33 percent, reduced Grade 3-4 haematological toxicity and the number of outpatient accesses.

Original languageEnglish
Pages (from-to)594-598
Number of pages5
JournalCancer Investigation
Volume25
Issue number7
DOIs
Publication statusPublished - Oct 2007

Keywords

  • 5-Fluorouracil
  • Chemotherapy
  • Cisplatin
  • Epirubicin
  • Gemcitabine
  • Metastatic disease
  • Pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: A dose-finding study'. Together they form a unique fingerprint.

Cite this